This study will determine if allopregnanolone (ALLO) improves depression and pain symptoms in patients who have a history of mild traumatic brain injury (TBI) [primary endpoints]. The investigators will also determine if ALLO improves functional outcome [secondary endpoint]. Participants in this study will receive an intravenous infusion of either ALLO or placebo. Behavioral assessments will be conducted during the infusion and at several time points post-infusion.

Start Date01 Jun 2026

Sponsor / Collaborator

VA Office of Research and Development

NCT07079761

/ RecruitingPhase 2IIT

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

Purpose: About 6.4% of the U.S. population suffers from posttraumatic stress disorder (PTSD). Trauma-focused psychotherapies are generally effective in PTSD, but responses vary greatly across individuals and PTSD subpopulations. Neurobiological factors impacted by life experiences, stress, and genetics can affect treatment responses. These factors can alter brain capacities needed to reprocess traumatic memories prevent them from triggering intensely distressing, disruptive, out-of-place responses.
For example, during psychotherapy for PTSD, trauma memory activation engages two competing brain processes that affect recovery: "extinction" versus "reconsolidation" of trauma-related emotional, physiological, and behavioral responses. This study tests whether a single intravenous (IV) dose of allopregnanolone (Allo) compared to placebo (which is non-active): promotes consolidation of extinction learning (sub-study 1) or blocks reconsolidation of physiological responses triggered by aversive memories (sub-study 2). The study also tests whether Allo compared to placebo affects retention of non-aversive memories.

Start Date04 Aug 2025

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT06580444

/ Not yet recruitingPhase 2IIT

Brexanolone to Target Concurrent Posttraumatic Stress Disorder (PTSD) and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

The purpose of this research study is to find out how Zulresso®/brexanolone influences Posttraumatic Stress Disorder (PTSD) symptoms and alcohol use.

Start Date28 Jul 2025

Sponsor / Collaborator

Yale University

[+2]

100 Clinical Results associated with Brexanolone

100 Translational Medicine associated with Brexanolone

100 Patents (Medical) associated with Brexanolone

2,905

Literatures (Medical) associated with Brexanolone

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives

Review

Author: Al-Qahtani, Zainah ; Al-Gareeb, Ali I ; Hussain, Nawar R ; Waheed, Huda J ; Al-Kuraishy, Hayder M ; Mustafa, Aya M ; El-Saber Batiha, Gaber ; Papadakis, Marios ; Albuhadily, Ali K ; Alexiu, Athanasios ; Alruwaili, Mubarak

Neurosteroids (NSs) are endogenous progesterone derivatives that act as natural allosteric modulators of GABA_A receptors, exerting distinct effects from conventional receptor agonists. They play critical roles in modulating neuronal excitability, cognitive function, and stress responses, and have shown potential in mitigating seizure severity and frequency, particularly in temporal lobe epilepsy (TLE). TLE is a common drug-resistant focal epilepsy characterized by complex pathophysiology involving hippocampal sclerosis, neuroinflammation, synaptic dysfunction, and alterations in GABA_A receptor subunits. Accumulating evidence indicates that NSs, including Allopregnanolone, brexanolone, and ganaxolone, may exert neuroprotective and anti-epileptogenic effects through both direct GABAergic modulation and indirect regulation of mTORC1, AMPK, and BDNF signaling pathways, as well as autophagy activation. Experimental studies demonstrate that NSs can prolong the latent period before epilepsy onset, reduce seizure recurrence, and potentially improve cognitive outcomes. However, clinical findings remain inconsistent, and prolonged NS exposure may lead to reduced receptor sensitivity. This review synthesizes current knowledge on the mechanistic roles of NSs in TLE, highlighting their potential as adjuvant therapies alongside antiepileptic drugs. Further translational studies are warranted to clarify optimal dosing strategies, identify patient subgroups most likely to benefit, and develop targeted NS analogues for refractory TLE management.

01 May 2026·NEUROPHARMACOLOGY

Assessing the utility of the neurosteroid zuranolone to modify alcohol-related behaviours

Article

Author: Pearl, Amy J ; Walker, Leigh C ; Ursich, Lauren T ; Maddern, Xavier J ; Lawrence, Andrew J

Alcohol use is a leading risk factor for premature mortality, yet effective pharmacotherapies remain limited. Neurosteroids, such as allopregnanolone, modulate γ-aminobutyric acid type A (GABA_A) receptors and influence alcohol-related behaviours. Zuranolone, an orally bioavailable synthetic analogue of allopregnanolone recently approved for postpartum depression, represents a potential candidate for therapeutic repurposing in alcohol use disorder (AUD). Here, we assessed the effects of acute and daily zuranolone on alcohol-related behaviours in a preclinical binge drinking model, comparing outcomes across sexes and contrasted to the effects of allopregnanolone. Allopregnanolone produced dose-related locomotor responses, characterised by mid dose transient hyperlocomotion and high dose sedation; the mid dose also reduced alcohol intake in both sexes. In contrast, zuranolone produced sex- and dosing schedule-related effects on alcohol consumption: acute high dose administration transiently reduced intake in males in the Latin square design, whereas mid dose administration increased intake under dose escalation in both sexes, particularly in males; however, total intake was unchanged across dosing schedules. Daily zuranolone transiently reduced alcohol intake in males during the first week only. In locomotor assays, acute high dose zuranolone induced sustained hyperactivity in males that was attenuated in females, supporting sex-related differences in sensitivity. Despite its structural similarity to allopregnanolone, zuranolone produced unique behavioural responses, suggesting their pharmacological profiles may differ. Overall, our data do not show robust reductions in alcohol intake following zuranolone administration across dosing schedules in either sex in preclinical models of binge drinking. Future studies are required to explore its potential relevance in comorbid AUD and affective disorders.

01 May 2026·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Structure-activity relationships of steroid and sterol neuromodulators on inflammatory markers in a murine microglial cell line

Article

Author: Zorumski, Charles F ; Mennerick, Steven ; Covey, Douglas F ; Shu, Hong-Jin

Neuroactive steroids are allosteric modulators of GABA_A receptors and are implicated in the etiology and treatment of neuropsychiatric disorders. Existing treatments are helpful but have drawbacks. Neuroactive steroids recently gained attention as rapidly acting antidepressants in postpartum depression and other indications. Unlike other GABA_A receptor modulators, neurosteroids may possess anti-inflammatory actions, potentially contributing to therapeutic benefit. Here we seek to understand neuroactive steroid structure-activity relationships relevant to these anti-inflammatory effects. We used murine microglial BV2 cells challenged with lipopolysaccharide (LPS) as an inflammation model. We investigated structure-activity profile of neuroactive steroids and oxysterol-like compounds on cytokine transcription. LPS increased transcripts for cytokines IL-1β, IL-6 and TNF-α. Both allopregnanolone and its enantiomer significantly suppressed these LPS-induced increases, with no effect in the absence of LPS. CONCLUSIONS: Our results suggest that neuroactive steroids exhibit a distinct structure-activity profile compared with their GABA_A receptor modulation effects. Certain neuroactive steroids may selectively target neuroinflammation. The enantiomer of AlloP could be a tool compound to differentiate anti-inflammatory effects of neuroactive steroids from GABAergic and other enantioselective effects.

205

News (Medical) associated with Brexanolone

13 Apr 2026

·www.fiercebiotech.com

Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates

Seaport has a crew of 58 full-time employees.\n Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.Boston-based Seaport is captained by CEO Daphne Zohar, a co-founder of Karuna, the biotech behind Bristol Myers Squibb’s approved schizophrenia drug Cobenfy. While Seaport has yet to disclose how many shares it would offer in an IPO, or at what price, we know that top of the list of spending priorities will be its lead depression candidate SPT-300, also known as GlyphAllo.SPT-300 is a prodrug of allopregnanolone—a naturally occurring neurosteroid that is marketed in a synthetic form as Zulresso for postpartum depression. The asset has been developed by Seaport’s Glyph platform, which is designed to enhance the bioavailability of oral drugs by reducing their metabolism in the body before they reach their intended target. The idea is that this should, in turn, reduce hepatotoxicity and other side effects.A Fierce 15 winner last year, Seaport has used the Glyph platform to retain allopregnanolone’s potency while delivering it as an oral drug. The company pointed to a phase 2a trial in 2023 that showed SPT-300 could reduce levels of cortisol in healthy volunteers as evidence that the drug could treat stress-related mood and anxiety disorders.Now, the biotech wants to use an IPO to fund an ongoing phase 2b study of SPT-300 in major depressive disorder (MDD) through to a topline readout next year, as well as launch a phase 3 study, according to an April 10 filing with the Securities and Exchange Commission.Some of the proceeds have also been earmarked to complete phase 2 studies of SPT-320, also known as GlyphAgo, a prodrug of agomelatine—an antidepressant available in Europe as Valdoxan but not approved by the FDA. Seaport has been banking on the ability of its Glyph platform to lower the dose required for effectiveness by reducing its metabolism in the liver and therefore removing the need for liver function monitoring. The aim is to launch a phase 2a study to determine whether SPT-320 can improve the sleep of patients with generalized anxiety disorder (GAD), as well as a phase 2b trial focused on GAD itself. Both studies would likely read out in 2028, according to the filing.When Seaport took SPT-320 into the clinic in September 2025, Chief Medical Officer Antony Loebel, M.D., pointed out that agomelatine’s “efficacy in GAD is already well established.” “The key question is whether we can achieve effective exposure at a lower dose, which would demonstrate GlyphAgo’s ability to avoid agomelatine’s dose-dependent liver issues,” Loebel said at the time. “We believe GlyphAgo has the potential to redefine the treatment landscape for GAD and represents an important clinical advancement for patients.”The remainder of the IPO proceeds will be used for SPT-348, a prodrug of a non-hallucinogenic analog of LSD, as well as for general R&D activities and working capital. Seaport’s CEO Zohar isn’t the only Karuna veteran on board—Karuna’s former CEO Steven Paul, M.D., serves as the chair of Seaport’s board of directors. The biotech employs 58 people and was originally assembled by PureTech Health—where Zohar was previously CEO—and supplied with $100 million when it launched in spring 2024. Seaport followed that up with a $225 million series B a few months later.Out of the $325 million raised to date, Seaport entered 2026 with a hefty chunk of funds—$233.7 million, to be precise—still intact, according to Friday’s filing. Hemab hopes for public listing Hemab also unveiled an intention on Friday to go public. The Cambridge, Massachusetts and Copenhagen, Denmark-based biotech has previously touted an ambition to become “the ultimate clotting company” and the highest priority recipient of its IPO proceeds will be sutacimig.The biotech has already tested the bispecific antibody in Glanzmann thrombasthenia, a rare genetic bleeding disorder caused by a deficiency of the platelet integrin alpha IIb beta3, which prevents blood from properly clotting. Hemab has previously pointed to phase 2 study as demonstrating that sutacimig achieved clinically meaningful bleeding reduction in these patients.The IPO funds would help finance a phase 3 study in Glanzmann thrombasthenia, as well as an ongoing phase 2 trial in another bleeding disorder called Factor VII deficiency, according to an April 10 filing with the SEC.There’s also a monovalent antibody, dubbed HMB-002, in a phase 1/2 study for von Willebrand disease, another genetic disorder that impacts blood clotting. Data have so far has shown that the drug can directly target the underlying pathophysiology of the disease.Further back in development, Hemab said it expects to take one of its preclinical assets into the clinic in the second half of 2026. The company employs 72 people full-time, split across the U.S. and Denmark. They are led by Benny Sorensen, M.D., Ph.D., who previously served at the likes of Codiak Biosciences and Alnylam Pharmaceuticals.Hemab’s strategy of using “targeted solutions rather than generic approaches” to clotting disorders has secured a steady stream of financings, from a $55 million series A haul in 2021, to a $135 million series B in 2023 and a $157 million series C last year. By the end of 2025, Hemab still had $185.5 million in the bank, according to the filing.Biotech IPOs rebounded in the first couple of months of 2026, although listings petered out again in March. Seaport joins a short list of companies that have more recently expressed an interest in going public, including respiratory-focused Avalyn Pharma and obesity biotech Kailera Therapeutics.

13 Apr 2026

·allsci.com

Seaport Therapeutics files to for Nasdaq listing to support oral psychiatric therapies

Seaport Therapeutics filed an S-1 registration statement with the SEC for an initial public offering of common stock on the Nasdaq Global Market under the ticker symbol SPTX. The share count and price range were not disclosed in the preliminary filing. Prior to the offering, the company raised USD 325 million in net proceeds from private investors, with shareholders holding greater than 5% identified as ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and PureTech, which the filing identified as a founder. Completion of the offering is contingent upon listing on the Nasdaq Global Market. Seaport Therapeutics is a clinical-stage company developing oral therapies for major depressive disorder and generalized anxiety disorder using a proprietary lymphatic-targeting prodrug platform called Glyph. The platform is designed to bypass first-pass hepatic metabolism, increase oral bioavailability, and reduce side effects associated with parent compounds. The company’s lead asset, GlyphAllo (SPT-300), is an oral prodrug of allopregnanolone targeting MDD with or without anxious distress. Its second candidate, GlyphAgo (SPT-320), is an oral prodrug of agomelatine targeting GAD. A third asset, Glyph2BLSD (SPT-348), is an oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD in preclinical development for depressive disorders including treatment-resistant depression and PTSD. GlyphAllo completed a Phase I trial in 99 participants in Australia, the filing stated, demonstrating therapeutically relevant allopregnanolone plasma exposures with an AUCinf of 6.6 ng·hr/mL per 1 mg dosed, compared to 0.7 ng·hr/mL per 1 mg with unmodified oral allopregnanolone in a prior third-party study. No treatment-related severe or serious adverse events were reported. In a Phase IIa randomized, placebo-controlled trial in 80 healthy volunteers in Australia using the Trier Social Stress Test as a biomarker of stress response, GlyphAllo demonstrated initial proof-of-concept and a favorable tolerability profile, as per the filing. The company initiated the Phase IIb BUOY-1 trial in July 2025, a global, randomized, double-blind, placebo-controlled study enrolling up to approximately 360 adults with MDD, with topline data anticipated in the first half of 2027. No interim or efficacy data from BUOY-1 were disclosed. For GlyphAgo, the filing stated that topline data from the single-ascending dose and crossover portions of a Phase I trial were reported in April 2026. In the crossover portion, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared to unmodified oral agomelatine and 10-fold lower pharmacokinetic variability. The SAD portion showed a 9.6 to 14.5-fold increase in dose-normalized exposure versus agomelatine. No liver-related adverse events were observed. The company stated plans to initiate a Phase IIa trial with topline data expected in early 2028 and a Phase IIb trial with topline data expected by the end of 2028. The filing noted that agomelatine is approved for GAD in Australia and for MDD in Australia and the European Union, but is not approved in the United States. The company was incorporated in Delaware in April 2024 and received its pipeline assets through an Asset Transfer Agreement with PureTech Health LLC and PureTech LYT Inc., amended in December 2025, covering rights to the Glyph technology. The filing identified co-founders Daphne Zohar and Steven Paul as having previously been central to Karuna Therapeutics, which was acquired by Bristol Myers Squibb in March 2024 for USD 14 billion. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 1Phase 2AcquisitionDrug Approval

06 Apr 2026

·www.prnewswire.com

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54) who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained through day 30 In the overall population, LPCN 1154 was well tolerated and demonstrated a differentiated safety profile with no reported adverse event, including somnolence or dizziness, occurring in more than 5% of the LPCN 1154-treated participants The Company plans to evaluate all available options going forward April 2, 20 26-- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). For more information on the trial design, refer to clinicaltrials.gov: NCT06979544. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D total score compared to placebo at hour 60 in the full analysis set and the primary was not met. The results showed LPCN 1154 to be well tolerated and demonstrated a favorable safety profile to support outpatient administration without the need for healthcare provider monitoring. No treatment-related severe or serious adverse events (SAEs) were reported; no cases of excessive sedation or loss of consciousness were observed; and no treatment-related discontinuations were reported. In a post hoc analysis of participants with a history of psychiatric conditions diagnosed using Mini-International Neuropsychiatric Interview (MINI, a structured diagnostic interview used to screen for and diagnose psychiatric disorders using DSM/ICD criteria), the Company identified signals that could indicate a potential development path for LPCN 1154. Table: Placebo-Adjusted HAM-D17 Score Change from Baseline NSS: Not Statistically Significant. Mixed model for repeated measures, least squares means placebo-adjusted difference. P-values are nominal except for Hour 60 Overall Population. Based on the results of the post hoc analysis of efficacy among participants with a history of psychiatric condition based on the MINI, the Company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD. While the Company is waiting for feedback from the FDA on such designations, the Company plans to preserve capital and engage with stakeholders, including investors, regulators, and advisors, to evaluate all options available to the Company going forward. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol, development of other product candidates, strategic transactions, partnerships, and other opportunities. The Company intends to complete its full analysis of the trial data in the coming weeks and plans to present the results at upcoming conferences. The Company thanks patients, investigators, and site staff for their contributions. LPCN 1154 is an oral formulation of brexanolone being developed to provide rapid relief of postpartum depression in a convenient, at-home treatment. It has potential as first line treatment choice for women with PPD. It also has characteristics that could be particularly beneficial to patients with severe PPD (including those with elevated suicide risk) for whom rapid improvement is a priority. LPCN 1154 is expected to offer a compelling safety profile for breastfeeding mothers. PPD is a major depressive disorder with onset either during pregnancy or within four weeks of delivery, with symptoms persisting up to 12 months after childbirth. Hormonal changes leading to GABA dysfunction are common in depression and pregnancy. Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide. Results from a recent survey (Truist Securities Research, January 2024) show that obstetricians believe approximately 20-40% of their patients may suffer from PPD. Further, obstetricians are comfortable making a diagnosis and prescribing antidepressants for PPD. Traditional antidepressants, not approved for PPD, have slow onset of action, side effects such as weight gain, and do not demonstrate adequate remission. Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2202 for treatment of treatment resistant depression, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultFast TrackDrug ApprovalBreakthrough Therapy

100 Deals associated with Brexanolone

External Link

KEGG	Wiki	ATC	Drug Bank
D11149	Brexanolone	N06A	DB11859

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depression, Postpartum	United States	SAGE Therapeutics, Inc.	19 Mar 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Perinatal asphyxia	Phase 3	United States	Lipocine, Inc.	16 Jun 2025
COVID-19	Phase 3	United States	SAGE Therapeutics, Inc.	18 Dec 2020
Respiratory Distress Syndrome, Acute	Phase 3	United States	SAGE Therapeutics, Inc.	18 Dec 2020
Arthropathy, Progressive Pseudorheumatoid, of Childhood	Phase 3	United States	Supernus Pharmaceuticals, Inc.	01 Jul 2016
Status Epilepticus	Phase 3	United States	Supernus Pharmaceuticals, Inc.	01 Jun 2015
Status Epilepticus	Phase 3	Austria	Supernus Pharmaceuticals, Inc.	01 Jun 2015
Status Epilepticus	Phase 3	Canada	Supernus Pharmaceuticals, Inc.	01 Jun 2015
Status Epilepticus	Phase 3	Denmark	Supernus Pharmaceuticals, Inc.	01 Jun 2015
Status Epilepticus	Phase 3	Estonia	Supernus Pharmaceuticals, Inc.	01 Jun 2015
Status Epilepticus	Phase 3	Finland	Supernus Pharmaceuticals, Inc.	01 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05329779 (CTgov)	Phase 4	Depressive Disorder	2	brexanolone (Brexanolone)	vgfwmzdtsj(upmkcnoppm) = aamqesjlag gqszqrheso (kwsudupnfm, icnwfxohru - lpksshrcwo) View more	-	22 Jan 2026
				placebo (Placebo)	vgfwmzdtsj(upmkcnoppm) = vwklgdlpsl gqszqrheso (kwsudupnfm, dpxjbumvim - ypjrkqfkik) View more
NCT04015869 (CTgov)	Phase 1	Alcohol Use Disorder	10	Allopregnanolone (Allopregnanolone)	hvueyqplho(wnqmgkgnez) = bifpkglqky cpqdlpmjkc (bjqysgxocv, 2.71) View more	-	22 Aug 2025
				Placebos (Placebo)	hvueyqplho(wnqmgkgnez) = yybnfnifsb cpqdlpmjkc (bjqysgxocv, 2.71) View more
NCT05645432 (CTgov)	Phase 2	Tinnitus	10	Brexanolone	pcqassdgcg = scmovqvfnv vzuvsefwlu (nevmfdklae, ycpcsyrzcs - pitzfucdhl) View more	-	12 Dec 2024
NCT05543746 (Company_Website) Manual	Not Applicable	Depression, Postpartum	23	LPCN 1154	ioletxhwmm(odffaiujfs) = gquetexhxe mpmsyhyrbd (nlvhtfutiu ) View more	Similar	25 Jun 2024
NCT05543746 (PRNewswire) Manual	Not Applicable	Depression, Postpartum	8	LPCN 1154	xpxyerjmue(foqnrxhjsn) = ncpkpnkqyx hamuzipptw (lxmlrkdffd )	Positive	06 Feb 2024
NCT05059600 (CTgov)	Phase 4	Depression, Postpartum	52	ZULRESSO®	xytvnihevh = lvmgcjwcbg tvlvgjlfdn (xsheydpcus, omubhlnpec - dqncpgjgrs) View more	-	19 Jul 2023
NCT02942017 \| NCT02614547 \| NCT02942004 (Pubmed) Manual	Phase 2/3	Depression, Postpartum \| Sleep Initiation and Maintenance Disorders \| Depressive Disorder ... View more	209	Brexanolone	vbcqhlmqdv(eswpljwijz) = ejqxjvvxzo ogblbxuhgv (mgrpdjayaw ) View more	Positive	30 Sep 2022
				Placebo	vbcqhlmqdv(eswpljwijz) = ookjalulaw ogblbxuhgv (mgrpdjayaw ) View more
NCT03665038 (CTgov)	Phase 3	Depression, Postpartum	28	brexanolone+placebo (Double-Blind Phase: Placebo)	huphmvyexi = rpejftumft qxndishcha (djvcpcqffy, fefbazpxyr - ahzgxijxxw) View more	-	11 Aug 2022
				Brexanolone (Double-Blind Phase: Brexanolone)	huphmvyexi = fkfrqqgnrd qxndishcha (djvcpcqffy, kchuzuowct - csctfbsqvi) View more
NCT04537806 (CTgov)	Phase 3	COVID-19 \| Respiratory Distress Syndrome, Acute	29	Placebo (Placebo)	hxvzysfloz = bknetgttwm vqpmqunpps (lhizvaoouq, bvadnunpiu - kjhofkzeug) View more	-	27 Jul 2022
				Brexanolone (Brexanolone)	hxvzysfloz = xzvfbqjfhp vqpmqunpps (lhizvaoouq, dsfajltcub - uisxgcxtgr) View more
NCT02277106 (CTgov)	Phase 2	Essential Tremor	25	SAGE 547 (Stage 1: SAGE-547)	kxkycqeegk = vvstakznuy vnqfhgrapn (qpegtywozn, gkobumiikd - cyeoewycgx) View more	-	29 Jun 2022
				SAGE-547+placebo (Stage 1: Placebo)	kxkycqeegk = lugnlhuyjy vnqfhgrapn (qpegtywozn, eunmuazeoy - czquwkumyr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis